Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eicosapentaenoic acid for inflammatory biomarkers and quality of life in ischemic stroke
IRCT20260201068719N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of eicosapentaenoic acid in ischemic stroke, sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Change in inflammatory biomarkers and Change in quality of life. Started Mar 2026; status: completed.
02
Drugs
eicosapentaenoic acid
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on IRCT20260201068719N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260201068719N1.